Gilead Sciences PE ratio GILD

Share price divided by earnings per share over the last twelve months, since 2010.

Today, Oct 23, 2026: n/m; losses over the last year
Last meaningful: 17.7×; Jul 2026
10-year median: 18.8×
10-year range: 6.2× to 317×
Peer median: 41.4×

Gilead Sciences has no meaningful PE ratio today: it lost $2.67 a share over the last twelve months, and a PE needs earnings.

It was last meaningful in Jul 2026, at 17.7×.

On the days it had one over the last ten years, its median was 18.8×, from 6.2× in Feb 2017 to 317× in Mar 2025.

PE ratio over time

median 18.8×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	17.7×	16.9×	24.0×
2025	19.3×	18.7×	317×
2024	118×	14.4×	214×
2023	17.4×	16.2×	33.2×
2022	32.4×	10.4×	33.6×
2021	12.4×	11.3×	301×
2020	60.1×	16.5×	63.5×
2019	31.6×	13.6×	58.4×
2018	51.6×	8.5×	60.0×
2017	8.2×	6.2×	9.2×
2016	6.6×	6.4×	8.8×
2015	9.3×	9.2×	18.6×
2014	16.5×	16.5×	45.2×
2013	40.7×	23.7×	40.9×
2012	22.6×	12.4×	23.8×
2011	11.9×	10.8×	13.6×
2010	10.6×	9.9×	12.1×

Against its peers

Companies in Drug Manufacturers - General nearest Gilead Sciences' size, closest first, today.

Company	PE ratio
GILDGilead Sciences	n/m
PFEPfizer	39.5×
AMGNAmgen	27.3×
BMYBristol-Myers Squibb	13.5×
MRKMerck	116×
ABBVAbbVie	80.7×
JNJJohnson & Johnson	40.0×
BIIBBiogen	44.4×
LLYEli Lilly and	42.7×
Peer median	41.4×

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Gilead Sciences

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.